Abstract
No public abstract is available from the verified source records.
Isabelle Fleury, Brian T. Hill, Toby A. Eyre, Chaitra Ujjani, Beenish S. Manzoor, Jennifer R. Brown, Hande H. Tuncer, Catherine C. Coombs, Nilanjan Ghosh, Lindsey E. Roeker, Nicolas Martinez-Calle, Nnadozie Emechebe, Joanna Meehan Rhodes, Alan P. Skarbnik, Wendy Sinai, Laurie Pearson, Frederick Lansigan, Yun Choi, Christopher E. Jensen, Bita Fakhri, Meghan C. Thompson, Deborah M. Stephens, Stephen J. Schuster, Michael Coyle, Andres Chang, Nancy Kaddis, Irina Pivneva, Annie Guerin, Mazyar S. Shadman
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the informCLL registry
10.1016/j.clml.2019.10.009 · 2020
Treatment patterns, healthcare resource utilization, and costs of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the US
10.1093/oncolo/oyad324 · 2024
Diagnosis and treatment of chronic lymphocytic leukemia: a review
10.1001/jama.2023.1946 · 2023
Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy
10.1002/ajh.27546 · 2025
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
10.1016/s1470-2045(17)30909-9 · 2018
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
10.1016/s1470-2045(24)00070-6 · 2024
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis
10.1111/bjh.15802 · 2019
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
10.1038/s41408-022-00721-6 · 2022
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon
10.1182/bloodadvances.2023011327 · 2024
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
10.3324/haematol.2018.193615 · 2018
Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group
10.1007/s00277-023-05304-4 · 2023
Treatment effectiveness of venetoclax-based therapy after Bruton Tyrosine kinase inhibitors in chronic lymphocytic leukemia: an international real-world study
10.1002/ajh.27563 · 2025
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
10.1080/10428194.2024.2310144 · 2024
Venetoclax-rituximab and emerging treatment strategies after c-BTKi exposure in relapsed/refractory CLL: a real-world cohort and literature overview
10.3390/cancers17193159 · 2025
Treatment discontinuation patterns for patients with chronic lymphocytic leukemia in real-world settings: results from a multi-center international study
10.1016/j.clml.2023.03.010 · 2023
Awareness, knowledge, and preferences of United States (US) patients with chronic lymphocytic leukemia (CLL) and their caregivers related to finite duration (FD) therapy and minimal (measurable) residual disease (MRD)
10.1182/blood-2021-145046 · 2021
Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment
10.1080/14796694.2024.2348440 · 2024
No additional external references are available.